Disease Landscape and Forecast Insights

Numerous drugs across multiple drug classes are available and used as monotherapies and/or adjunctive therapies for the treatment of bipolar disorder (BPD). The treatment armamentarium for BPD is…

Marketed therapies are often sufficient in early stages of Parkinson’s disease (PD), but as the disease progresses, they impose a considerable pill burden, progressively lose efficacy, and are…

Immune checkpoint inhibitors continue to revolutionize the treatment of a wide range of solid-tumor and hematological malignancies, with a growing list of approvals and label expansions. The Immune…

The revolution in genomic sciences has spurred significant drug development in rare diseases, approximately 80% of which have a genetic etiology. The field of gene-based therapies, while still in…

Market Outlook The expedited approvals of Novartis’s Kymriah for the treatment of pediatric and young adult patients with relapsed or refractory B-cell acute lymphocytic leukemia (ALL), and…

The migraine market stands on the verge of a renaissance; new and exciting therapies targeting the CGRP peptide could reach the market beginning in 2018. Two broad types of approaches are in final…

Device choice has long been a driver of sales of certain inhaled therapies, especially those available in multiple inhalers. With generic LAMAs and LABA/ICS FDCs anticipated to launch in the United…

Immune checkpoint inhibitors are the hottest drug class in oncology and are poised to continue revolutionizing the treatment algorithms of a wide range of solid-tumor and hematological malignancies…

The approval of the first oncolytic viral therapy, Imlygic, in the United States and EU5 in 2015 and 2016, respectively, marks a significant milestone for cancer vaccines and viral therapies,…

With a growing population and an enormous clinical need for improved treatments, the market for Alzheimer’s disease (AD) pharmacotherapies represents a massive commercial opportunity that…

Abstract Introduction: With a growing number of biosimilars in development and the launch of the first FDA-approved products in 2015, biosimilars are set to gain an increasing share of the…

Gaining physician confidence is critical to securing a meaningful position in developed markets; therefore, understanding their concerns about biosimilar products should be an important part of…